
It starts
with nacre.
Nacre from Pinctada maxima is the starting material for our research. A marine origin, opening new research paths in bone regeneration.
FRContact Bone regeneration · Dental programme
Nacre.
A new horizon for bone.
Late preclinical stage

From material to medical device
Restoring bone volume is a key need in many dental procedures. Bionacre® Bone Graft, our lead programme, explores an approach combining scaffold function, biological interaction and progressive remodelling. The ambition is to create conditions favourable to new bone formation.

Nacre from Pinctada maxima is the starting material for our research. A marine origin, opening new research paths in bone regeneration.
The concept under investigation
Granules designed to occupy the bone defect and provide a scaffold for repair.
The interface with cells, proteins and fluids is studied to understand the tissue response.
Assessments track how the material evolves and resorbs over time.
The objective is to support new bone formation and progressive replacement of the biomaterial.
This sequence describes the development objective and the processes assessed in preclinical studies. It does not establish a demonstrated clinical benefit of Bionacre® Bone Graft.
Bionacre® Bone Graft in detail
Defined clinical situations guiding Bionacre® Bone Graft development.

Socket filling after extraction, to investigate preservation of alveolar ridge dimensions.

Filling alveolar bone defects associated with dental implant placement.

Intrabony defects around natural teeth.

Horizontal or vertical bone volume augmentation before or during implant placement.

Bone volume augmentation in the posterior maxilla in preparation for implant placement.
Schematic illustrations · Teal: illustrated grafting area.These are target applications for Bionacre® Bone Graft development, not authorised indications.
The concept links placement in the bone defect, interaction with cells and biological fluids, and assessment of remodelling and new bone formation. This sequence guides preclinical evaluation; it is not an established clinical outcome.
Explore Bionacre® technologyThe programme is in the final stage of preclinical development. Applications to conduct a clinical investigation in Europe are being prepared.
A 510(k) submission to the FDA is planned for early 2027. This timeline is prospective; submission does not constitute market authorisation.
Are you a clinician, researcher or industry partner? Contact our team to discuss available data and Bionacre® Bone Graft development.
Request documentation ↗Discuss the programme
Questions about target applications, available data or next steps? Contact our team.
Ask about Bionacre® Bone Graft